Debut Issue, Fall/Winter 2014 The Magazine of the Multiple Myeloma Research Foundation

Multiple myeloma at a transformational moment

Making precision medicine a reality for multiple myeloma patients we are curing cancer accelerator The Magazine of the Multiple Myeloma Research Foundation | Fall/Winter 2014

Features

Our pipeline is the strongest in our history.

Researchers who used to compete now collaborate. 5 THE ACCELERATORS 6 KNOW EVERYTHING THAT 12 COVER STORY Technology companies are How the MMRF reached this IS HAPPENING IN MYELOMA The MMRF CoMMpass StudySM stepping up. Sequencing transformational moment. Introducing the redesign seeks to make precision of themmrf.org. medicine a reality. individual genomes is WE ARE providing exciting PROUD TO SHOW YOU Drug Development People Events roadmaps to a cure. WHAT THE MMRF 7 CLINICAL TRIAL NEWS 14 DONOR PROFILES 18 MMRF ANNUAL FALL GALA Life expectancy has HAS ACHIEVED 10 MULTIPLE MYELOMA 16 MMRF LEADERSHIP 20 MMRF CHICAGO MASTER PROTOCOL AWARDS DINNER nearly tripled. And we IN 2014. 11 MMRF RESEARCH AWARDS MMRF in the News 21 MMRF LAUGH FOR LIFE: have launched our NOW NEW YORK 26 MMRF MEDIA HIGHLIGHTS fundraising campaign, 22 MMRF TEAM FOR CURES the largest in our history. 25 INDEPENDENT EVENTS 27 CALENDAR To learn more, or to make ABOUT THE COVER a donation, please visit The promise of personalized medicine. The more we learn about cancers affecting different parts of the body, themmrf.org. the more biologically similar we find them to be. See what we are learning in the groundbreaking MMRF CoMMpass StudySM on page 12.

SPONSORS We thank our sponsors for their support of Accelerator, The Magazine of the Multiple Myeloma Research Foundation

3 The Accelerators A letter from Walter M. Capone How the MMRF reached this transformational moment Dear friend of the MMRF,

The mission to cure multiple myeloma has entered a critical, transformative time. Working with strong partners in industry and academia, the MMRF is leading new, bold initiatives and advancing promising therapies to bring overwhelming force in the fight against myeloma.

So far this year, we’ve brought 3 new classes of drugs into our clinical study portfolio (p. 8) and are launching one of the first targeted therapy trials in myeloma. The MMRF CoMMpassSM Study, cornerstone of our precision medicine initiative, is on track to complete enrollment by year end. We have identified thousands of mutations and are seeing patients respond well to the six treatment approaches that predominate in first line treatment. Learn more about our progress (p. 12). Driven by their own experiences with Part 2: The MMRF CoMMpassSM Study centers. This is the idea behind the MMRF Our fundraising efforts have received a strong boost from two cancer, and/or a personal mission, the “Open science” is a central tenet of Researcher Gateway, which centralizes new funds (p. 14), and we are in the process of launching the NOW men and women who lead the MMRF are the MMRF’s strategy to accelerate and shares genomic data to accelerate campaign, the largest capital campaign in MMRF history. united in their goal to disrupt the status a cure. So all data from the MMRF discovery of individualized treatment The NOW campaign is the first of several changes that we have made quo and accelerate the path to a cure. CoMMpass Study is being placed on the approaches, biomarkers, diagnostics and at the MMRF, which include a user-friendlier website (p. 6) and our MMRF Researcher Gateway, a public new drug targets. The result of the team’s work, which redesigned magazine. portal, to accelerate data sharing and includes leadership roles in Clinical Part 4: The MMRF CoMMunity Gateway hypothesis generation for new clinical Research, Clinical Operations, Finding a cure depends on everyone in As we move into 2015, we are designing new academic, industry trials. CoMMpass is tracking 1,000 Translational Research, and Strategic the myeloma community — researchers, and government researcher partnerships, and are developing new patients from initial diagnosis through Partnerships, has four key components: industry, clinicians, and patients. That is networks, research tools, and international clinical trial consortia. their course of treatment for at least 8 why the MMRF established the MMRF Part 1: The Multiple Myeloma years with sequential tissue sampling I can see the future. We are closing in on it faster than ever — CoMMunity Gateway, to empower Genomics Initiative to identify how a molecular profile may it is a world without cancer. patients to become active participants The MMRF was the first to sequence affect response to treatment. in their own care by sharing their On behalf of all of us at the MMRF, we thank you for your support the myeloma genome and put the Part 3: The MMRF journey in our search for better, more and wish you and your loved ones a happy New Year! results in a centralized repository Researcher Gateway targeted treatments. for researchers to share through the Sincerely, Keenly aware of the bottlenecks typical Initiative’s Genomics Portal. The result in cancer research, the MMRF leadership Anne Quinn Young, M.P.H., Vice President, is the largest data set ever published team aims to engage all possible stake- Development and Strategic Partnerships; in myeloma. Kathy Giusti, Founder and Executive Chairman holders, including researchers, drug MMRF and MMRC; and Walter M. Capone, Walter M. Capone companies, and academic/community President and Chief Executive Officer. President and Chief Executive Officer, MMRF

THEMMRF.ORG 5 Know everything that Drug Development is happening in myeloma MMRC pipeline offers promise to patients

Our comprehensive new website is organized with you in mind. It has been an exciting year for clinical trials.

The most important element in the to add content in the months to come, who specialize in their particular area of Ed Johnson, a patient whose multiple quest to cure multiple myeloma is so visit themmrf.org today — and check genomics, and sign up for clinical trials that myeloma has relapsed, was researching “We have opened six information. Circulating it quickly back often. might be right for them. treatments that have become available incredibly exciting new among the people who need it is key to since his diagnosis seven years ago. Discover these patient resources Clinical Trial Finder the success of the MMRF, and critically “Here’s another one,” he remembers trials for multiple myeloma Find a host of useful tools, starting Take action! Play a more active role in important to the researchers, clinicians, saying. “Here’s another one. And with these three: your healthcare, gain access to promising patients who are running pharmaceutical and biotechnology here’s another one. There are a lot new research treatments before they of options,” he continues. “A few years out of treatment options. companies, and patients who are Free e-Newsletter are widely available, and help advance ago it was option A and ‘we’ll have to pressing for a cure. Sign up for our monthly newsletter We are confident that medical research to bring us closer to hope that works.’” and get updates about new treatments, The new MMRF website is the conveyor finding a cure. they will prove to have new trials, and more. of everything that is known and being Call: 1-866-603-6628 Now, we are poised to make even a significant impact for greater progress toward a cure. This discovered in multiple myeloma. It is easy MMRF CoMMunity Gateway Email: [email protected] year, the Multiple Myeloma Research many of our patients.” to use and organized to help you find out Participate in our search for better, Professional Education Consortium (MMRC) opened six new Fiona An, M.D., about a treatment or clinical trial, a new more targeted treatments online. As therapies, to all-oral regimens. We are —  Gain access to significant clinical data clinical trials. These represent some Senior Vice President development in our understanding of the more patients’ genomes are sequenced confident that they will prove to have published at major medical congresses of the most promising treatments in of Clinical Research disease, and useful resources that can and mutations are discovered, the hope a significant impact for many of our ASH, ASCO, EHA, and IMW. Learn from for the MMRF and make a difference in your life. development today. “Together with our is that patients can connect with other patients,” said Fiona An, M.D., Senior MMRC key opinion leaders in multiple myeloma committed and world-class partners, we patients, then engage with researchers Vice President of Clinical Research for The website is dynamic, just like the who will highlight key clinical data. have opened six incredibly exciting new the MMRF and MMRC. field of multiple myeloma research. It Visit the MMRF website to view trials for multiple myeloma patients who is designed to update you on promising CME-accredited webcasts. are running out of treatment options. Our mission is to keep that pipeline new developments and discoveries as There is such a robust pipeline of filled for Ed Johnson and other patients they occur. In this spirit, we will continue promising therapies — from monoclonal like him. The Johnson Family: Ed, Annie, Augie antibodies to first-in-class novel and Louis.

6 THEMMRF.ORG DRUG DEVELOPMENT 7 Hope for patients with relapsed myeloma These breakthrough MMRC clinical trials provide hope for relapsed patients who may have The strength of the consortium few options and whose cancer has not responded to previous treatments. The Multiple Myeloma Research Consortium (MMRC) is the first collaborative research model of its kind that brings together academic The MMRC, working with our industry Ibrutinib (Novel mechanism) monoclonal antibody. The MMRC is also Kyprolis.® A mechanistically distinct way and community cancer centers with and academic research partners, This multicenter, Phase I/IIb trial is studying this investigational treatment of inhibiting this critical proteasome industry to advance innovative phase themmrc.org identified a strategy to drive drug studying ibrutinib in combination with in combination with Revlimid® and pathway may provide benefit for patients 1 and phase 2 clinical trials of today’s discovery and development for patients Kyprolis® in patients with relapsed dexamethasone. The lead MMRC who are relapsed and refractory. The most promising drug candidates. University and Chairman of the with multiple myeloma at a rapid or relapsed and refractory multiple investigator is Tom Martin, M.D. of the lead MMRC sites are Emory University, The MMRC leads a robust clinical MMRC Steering Committee and the pace — studying the most promising myeloma. Oral ibrutinib blocks a University of California, San Francisco. overseen by Sagar Lonial, M.D., and the network of 21 Member Institutions Project Review Committee, praised therapeutics and most diverse science protein called Bruton’s tyrosine kinase. University of California, San Francisco, across the country that work together the MMRC for its diligent work this Ixazomib (MLN9708) on parallel paths. Because of the It is currently approved by the U.S. overseen by Jeffrey Wolf, M.D. as one. MMRC Member Institutions year and the new lifesaving drugs it (Novel agent) complex nature of the disease, we are Food and Drug Administration (FDA) are supported by an advanced is developing in collaboration with This Phase I/II trial is studying ixazomib Additional Clinical Trials prioritizing three core approaches — for the treatment of Chronic infrastructure, including a cutting- industry partners. “The ability of our (MLN9708) in combination with The MMRF and the MMRC have immunotherapies and antibodies, Lymphocytic Leukemia. The lead edge Tissue Bank and IT systems that myeloma-focused clinicians to rapidly Pomalyst® and dexamethasone for accelerated more than 50 clinical trials novel drug mechanisms, and targeted MMRC investigator is Ajai Chari, M.D. enable rapid, seamless collaboration. move laboratory data into real-world relapsed or relapsed and refractory and are currently supporting many trials therapies — to identify therapeutics of Mount Sinai Hospital. clinical trials is a real strength of the multiple myeloma. Ixazomib is the first oral at various stages of development. For Sagar Lonial, M.D., Vice Chairman with the most promise and deliver them consortium. New treatments and Selinexor (KPT-330) proteasome inhibitor in development. If more information about the MMRF’s of Clinical Affairs Department of to patients in a meaningful timeframe. combinations represent the future (Novel mechanism) approved by the FDA, it could provide an current research work and research Hematology and Medical Oncology, of how we will treat myeloma. The Following is information on our six This Phase I study is evaluating easier and more convenient route of drug services we can provide, please Winship Cancer Institute, Emory strides made just this year will help new trials which are currently open for the Selective Inhibitor of Nuclear administration for many patients than contact Daniel Auclair, Vice President our patients in their goals to control enrollment: Export (SINE) selinexor (KPT-330) current treatments in this class, which are of Translational Research at and ultimately cure the disease,” in combination with Kyprolis® and administered by IV infusion or injection. [email protected]. Dr. Lonial said. n Marizomib (NPI-0052) dexamethasone in patients with The lead MMRC site is the City of Hope (Novel agent) relapsed or relapsed and refractory National Medical Center, overseen by This Phase I, multicenter, open-label, multiple myeloma. Selinexor is the first Amrita Krishnan, M.D. Robust Clinical Pipeline for Multiple Myeloma dose-escalation study is evaluating the drug in the SINE class to be studied in The MMRF and the MMRC are supporting a pipeline that We have prioritized three core approaches to identify combination of marizomib, Pomalyst® CB-5083 (Novel mechanism) multiple myeloma. MMRF played a key pursues the most promising therapeutics to help extend treatment options — immunotherapies and antibodies, and low-dose dexamethasone (PMD) This Phase I, open-label, dose-escalation role in advancing the study of selinexor and save the lives of people living with multiple myeloma. targeted therapies, and novel mechanisms. Approved in patients with relapsed or refractory first-in-man study of CB-5083, the first in multiple myeloma through the grant Immunotherapies Targeted Novel multiple myeloma. Marizomib is a novel p97 inhibitor to enter clinical trials. of a Biotech Investment Award in 2010 and Antibodies Therapies Agents Mechanisms ® proteasome inhibitor in the same class Several MMRC member institutions Doxil to the drug’s developer, Karyopharm. Elotuzumab AT7519 Ixazomib ABT-199 Ibrutinib Kyprolis® as Velcade® and Kyprolis.® MMRC has worked closely with manufacturer The lead MMRC investigator is SAR650984 GSK21110183 Marizomib ARRY520 Panobinostat Pomalyst® also studied this drug in Phase I as a Cleave Biosciences on the preclinical Andrej Jakubowiak, M.D., Ph.D. at Siltuxumab MLN128 Oprozomib CB-5083 Selinexor Revlimid® single agent. Investigators believe that work, which suggested activity in the University of Chicago. OSI906 Ganetespib Thalomid® it can work in patients who are resistant multiple myeloma. CB-5083 targets a PD0332991 Velcade® to other proteasome inhibitors. The SAR650984 (Antibody) novel protein that is involved in protein TKI258 lead MMRC investigator is Paul This is a Phase I study of SAR650984 degradation and the proteasome Richardson, M.D. at the Dana-Farber as a single agent for the treatment pathway, and inhibits this pathway at New Diagnostic Approaches

Cancer Institute. of relapsed or refractory multiple a different intervention point than the n Janssen Diagnostics, LLC, CELLSEARCH® n Sequenta myeloma. SAR650984 is an anti-CD38 proteasome inhibitors, Velcade® and Circulating Tumor Cell (CTC) Test LymphoSIGHT™

8 THEMMRF.ORG DRUG DEVELOPMENT 9 The MMRF goes to Washington A meeting with key regulatory agencies, industry, academia and patients yields encouraging results.

On October 22nd, the MMRF hosted a “Myeloma is an incredibly complex, The Multiple Myeloma Master Protocol workshop in Washington, D.C. to discuss heterogeneous disease. There is would enable several Phase II clinical and advance the development of a an acute need for new therapies, trials to take place at the same time but Multiple Myeloma Master Protocol — particularly for patients whose cancer within a single study design. Patients a novel clinical trial design that would has relapsed,” said Shaji Kumar, M.D., enrolled in the trial would be assigned allow multiple new therapies targeting Mayo Clinic College of Medicine. to an appropriate treatment arm based specific mutations to be evaluated “The evidence suggests that this is on a genetic analysis of their cancer. MMRF Research Awards simultaneously, completing in a single the right approach to accelerate the Decisions to advance a drug to Phase III trial what would normally require five development of targeted treatments. testing in a specific genetic subgroup, or fund important discoveries or more individual studies. This may When finalized, this Master Protocol to test a different drug in this subgroup, cut years off traditional approaches, will be a major landmark for the could be more quickly expedited — with MMRF Research Fellow Award delivering potential breakthrough multiple myeloma community.” the goal of getting new drugs to patients MMRF Senior Research Awards MMRF Research Fellow Award therapies to patients faster than ever faster than ever before. MMRF Senior Research Awards fund In 2014, the MMRF funded before. More than 80 participants from cutting-edge basic science and pre- supports innovative research conducted While real progress has been made in $1,375,000 in Senior the U.S. Food and Drug Administration, clinical research focused on accelerating by talented young investigators working the battle against multiple myeloma, the National Cancer Institute, the the development of novel treatments. under the supervision of a senior Research and Research there is still more work to do to bring pharmaceutical, biotech and diagnostic research mentor. new, effective, personalized treatments Qing Yi Fellow Awards. The MMRF industries, academic centers, and to patients. The MMRF is committed to The Cleveland Clinic Foundation Kim Chan Chung the patient community attended the acknowledges generous moving the project forward as quickly University Health Network, Toronto workshop and endorsed a plan to move Kari Hemminki contributions from Amgen, as possible. Ontario, Canada forward with the development of this German Cancer Research Center, Bristol-Myers Squibb, novel study protocol. Heidelberg, Germany Jens Lohr Dana-Farber Cancer Institute Genentech, Millennium, David Toczyski Onyx, Celgene, and Novartis University of California — John Simmons San Francisco (UCSF) National Cancer Institute in support of the awards.

Stephen Nutt Eric Smith The Walter and Eliza Hall Institute Memorial Sloan-Kettering of Medical Research, Australia Cancer Center

Mike Chapman The University of Cambridge, United Kingdom

DRUG DEVELOPMENT 11 Data Update

We anticipated: Making precision medicine a reality n A wide spectrum of different myeloma subtypes at initial diagnosis

for multiple myeloma patients n A variety of treatment approaches

n A small proportion of patients with complex mutation patterns

We are seeing: n Over 10,000 mutations, or mutation combinations; myeloma is a heterogeneous type of cancer

n Six treatment approaches predominate in first-line treatment for yelomam patients, with bortezomib- lenalidomide-dexamethasone prevailing as the most commonly used therapeutic regimen (~60% of cases)

n Patients are responding well — medications are holding a majority of patients’ disease in check for at least Individual biology Progress report three years, and counting Understanding the genomic The MMRF CoMMpass study is making n CoMMpass data (clinical and underpinnings of individual patients enormous progress thanks to all the genomic) from interim analyses n Some unique mutations and mutational is the goal of the MMRF CoMMpassSM inspiring patients and researchers who 1–4 are included in the MMRF patterns not previously discovered, or Study. This groundbreaking study, the have joined it. Highlights of the study Researcher Gateway which can if discovered, not previously confirmed, cornerstone of the MMRF precision include the following: be accessed by researchers around until now medicine initiative, is designed to profile the world SM n 1,211 patients have been screened The findings of the CoMMpass Study 1,000 newly diagnosed patients by n Data and material sharing are placed on a public portal (the MMRF obtaining their clinical and genomic n 743/1,000 active patients are collaborations will be initiated in Researcher Gateway). The resulting data information at an unprecedented level enrolled* December 2014 allowing CoMMpass set will be the largest, most comprehensive of detail — from initial diagnosis for at n 84 research sites are enrolling to “piggyback” on other trials catalog of multiple myeloma including the least 8 years — and then linking this patients in the U.S., Canada and Spain largest set of whole genome sequences. data to patients’ clinical responses. n CoMMpass data is reviewed and It will provide far more information than By revealing the biological basis of analyzed every six months; the 6th is possible from many current cancer myeloma in this manner, and the Interim Analysis has been completed, tissue banks that typically include one disease’s response to treatments, it will which includes clinical data for 626 sample per patient. n accelerate new and even more effective patients, and 363 patients with full therapies for patients, and perhaps the genomic profiling results beginning of cures for many subtypes. It is yet another way

*As of November 1, 2014 we are curing cancer.

12 THEMMRF.ORG The Elseys Announce a $1 Million Matching Campaign The Linda Rodgers Emory Fund Precious Cat founders Dr. Bruce and Kathy Elsey donation $1 million gift establishes a fund for establishes a fund to accelerate a cure. accelerating immunotherapy in multiple myeloma.

A new initiative from committed decided to make a transformative A strong partnership Linda Rodgers Emory, a longtime spreading to other parts of the body, and creative supporters commitment to the MMRF and began The Elseys have funded nearly supporter of the MMRF and multiple helping the immune system increase The power The Elseys, longtime supporters of donating a portion of purchases of $7 million to help discover and myeloma patient, has made a generous its effectiveness at eliminating cancer of immunotherapy the MMRF, will match contributions their Precious Cat Litter products advance numerous new drugs into donation of $1 million. This funding will cells. Tremendous strides are being Immunotherapy leverages the power of of the MMRF community by 100% to the MMRF. MMRC clinical trials, and to fuel the help expedite a pipeline of immuno- made in other cancers using these the best disease-fighting machine ever up to $1 million before the end of 2014. Precision Medicine Program featuring therapeutic agents to benefit myeloma types of approaches, including trials #CatsAgainstCancer created — the human immune system — The gift establishes Dr. Elsey’s Fund the CoMMpass Study,SM the MMRF patients, and enable critical research presented at the Annual American In addition to the to identify, target, and overcome threats to Cure Cancer. Researcher Gateway and the MMRF into the basic biology and mechanisms Society of Clinical Oncology (ASCO) current challenge, to our body. By using proteins and CoMMunity Gateway. 2014 marked of immune response in myeloma. Meeting. This funding will be used to other compounds made by the body “Our family has cancer,” he says. “We the Elseys have the fourth year of this collaboration. rapidly advance trials into the clinic. or developed in the laboratory, we are feel blessed that our family can support partnered on “I made this gift to the MMRF to help discovering new ways to activate, train Kathy Giusti’s much larger family that a campaign to “Kathy and Bruce’s visionary leadership build and support the best portfolio of “Linda Rodgers Emory has provided and strengthen the immune system to also has multiple myeloma. Kathy Giusti’s raise awareness and inspirational support of the immunotherapeutic agents possible,” profound philanthropic leadership recognize and shut down cancerous cells. family is the MMRF and they are and funds for myeloma research. The MMRF’s scientific and patient programs said Ms. Emory. “I am confident that to advancing myeloma research and By permitting the immune system working tirelessly to quickly find a cure.” campaign, #CatsAgainstCancer, spans have enabled advances that would the MMRF will assemble the best drug development over the years, to increase its effectiveness, patients Facebook, Twitter and Instagram using otherwise not be possible,” said Walter scientists and researchers from around for which we are extremely grateful,” may be able to avoid more toxic and A transformative commitment the Photala photo sharing platform to M. Capone, Chief Executive Officer and the world to focus on this exciting area Kathy Giusti said. “This contribution debilitating therapies. The MMRF This new initiative from the Elseys is not enable users to share their individual President of the MMRF. “In addition, of cancer research and work diligently will help us build the most robust is building a robust pipeline of the first time they’ve provided generous experiences and support the campaign’s they have inspired further support to speed clinical trials of promising pipeline of immunotherapeutic agents immunotherapeutic approaches from support to the MMRF. mission. As part of the campaign, through generous contributions new approaches to benefit all multiple for myeloma, and will allow us to build novel antibodies to modified immune- system cells to vaccine-based therapies When Kathy Elsey users can download a coupon from the from thousands of other donors. The myeloma patients.” collaborations with experts in that precisely target myeloma. was diagnosed with campaign landing page that allows them establishment of Dr. Elsey’s Fund to immune biology in myeloma and Although it is not entirely clear how multiple myeloma to save $3 on their next purchase of Cure Cancer will allow us to drive closer in other cancers.” immunotherapy treats cancer, it is in 2009, she and a 40-pound bag of Precious Cat Ultra than ever towards a cure.” thought to stop or slow the growth Dr. Bruce Elsey wanted to do everything Litter. For every $3 saved, Precious Cat of cancer cells, or stop cancer from they could to attain a cure. Already will donate $3 to MMRF. Kathy and Dr. Bruce Elsey with their Linda Rodgers Emory, philanthropist, MMRF generous philanthropists, the Elseys grandchildren. supporter, and multiple myeloma patient.

14 THEMMRF.ORG PEOPLE 15 Leadership News Behind the Titles The MMRF welcomes three new cancer fighters Get to know the MMRF team members.

Fiona An, M.D., Senior Vice Daniel Auclair, Ph.D., Sharon Saias, President of Clinical Research Vice President of Translational Senior Director of Marketing Alicia O’Neill, Director of Endurance Events, walks the walk — and runs the races. Research Fiona is a global clinical research Sharon’s marketing career spans more When Alicia O’Neill founded the MMRF Marathons, and development professional with Daniel, who managed than 25 years, with both client and Endurance Events program in 2007, triathlons, and significant experience in oncology and the MMRF Multiple agency experience in consumer and her first project was the New York City other endurance hematological malignancies in both Myeloma Genomics B-to-B marketing across a wide range Marathon. Twenty MMRF Team for events often academia and the pharmaceutical Initiative from of industries. Prior to joining MMRF, Cures members raised $125,000 and sell out fast, and industry. She recently joined the MMRF 2007-2010, rejoined Sharon served as Director of Marketing “we were on our way,” she says. In 2008, athletes who want from Pfizer, Inc., where she worked as the company in 2013 after three years at at Frontier Communications, Senior 63 runners ran eight world-class races, to compete gain a Senior Director of Global Oncology the Broad Institute of MIT and Harvard. Brand Manager with Kraft Foods, and including the Boston and Chicago entry by joining Clinical Development. Digital Marketing Manager at illycaffè. marathons. “That first ‘real year’ of an official charity As senior leader in the Cancer She previously ran her own consulting a full program, we raised $325,000.” team. When they Fiona began with Program at the Broad Institute, Daniel business where she served both agency become part of This year, MMRF Endurance Events Alicia O’Neill participates in the molecular biology was involved with a wide range of and corporate clients, and included such Team for Cures, raised more than $3 million with over Berlin Marathon. and preclinical academic and industry collaborations companies as Communications Plus, they agree to 1,000 participants in 20 events. Success oncology research centered around cancer genomics and AMBI/CardiaNutrition, IBM, Lucent fundraise at a certain level and “they get involved. 2015 will also introduce comes, in part, from the enthusiasm, at the Chinese Center personalized medicine. Technologies, and Reader’s Digest. learn about us,” says Alicia. “Over time, the Fifth Avenue Mile, one of the crown creativity, and energy of Alicia and her for Disease Control and Prevention, they become our champions.” In the jewels of the New York Road Runners, Prior to this, he spent a decade in the Sharon began her career at Ogilvy & staff, Jane Hoffmann and Kelley Ward. the University of Chicago, and the Scripps last IRONMAN event, they raised more and will, of course, continue to offer Research Institute, then expanded into pharmaceutical industry, most Mather where she managed such high- “I love the relationships, the ideas, than $8,000 per person. “They become the traditional 5K Walk/Runs in which oncology clinical research and drug notably at Bayer Healthcare where he profile accounts as AMEX, AT&T and building new programs into franchises,” connected to us, and excelled.” supporters of all ages participate. development at Pfizer. led a number of cancer drug discovery Vanguard Financial Alicia says. Perhaps most inspiring is efforts. Services. Sharon MMRF Endurance Events have grown “We want to mix things up and give the kind of outcome she experienced Prior to Pfizer, Fiona worked in received her B.B.A. from that first New York City Marathon our supporters lots of different ways Daniel holds graduate and post- in the first MMRF association with an Business Development and New in Marketing to include U.S. and international to participate, and keep it fun and graduate degrees in Biochemistry IRONMAN® triathlon. “70 percent of Products Marketing at Forest from Hofstra marathons, cycling events, triathlons, interesting,” she says. and Nutrition from the University of the people on the team had never heard Laboratories, Inc., as well as product University. and more. The MMRF is the Official Montreal and conducted postdoctoral management in Global Strategic of the MMRF when they signed up,” she Charity Partner of 2015 IRONMAN Alicia keeps things interesting for studies at the Dana-Farber Cancer Marketing at Janssen (Johnson & explains, “and we wound up raising more Lake Placid and next year will add the herself, too. “I have done an event for Johnson) for Velcade. Institute/Harvard Cancer Center. money with that event than any event Spartan Race™ in Citi Field and Fenway the MMRF team every year: NYC ever.” More important, “we created Park as well as a couple of Ragnar® Marathon, Boston, London, Marine Fiona has an M.D. from Beijing Medical incredible ambassadors who will Relay races. In addition, there are plans Corps Marathon, and most recently, University, an M.S. from the University continue to support us in other events.” for a 10-mile kayak event across Long Berlin. I think it’s important to “walk the of Chicago (concentration in Cancer Island Sound. But, Alicia emphasizes, walk” (or run the run!). Almost always, Biology), and an M.B.A. from Stern School you don’t have to be a super athlete to I am the top fundraiser on the team.” of Business at New York University.

16 THEMMRF.ORG PEOPLE 17 The MMRF Fall Gala Is a Glittering

Success 1

2

3 4 5

The premier fundraising Special Correspondent for NBC News of the MMRF. “The money we event of the MMRF brought and multiple myeloma patient, was raise is critical to developing the in more than $2,600,000 awarded the MMRF Spirit of Hope next generation of genomic and that will significantly help Award, and William N. Hait, M.D., immunotherapeutic treatments as we 1 Ph.D., received the MMRF Corporate move closer to discovering the cure for 1.  New Orleans jazz filled the air. to fuel the research that Chair Award. Dr. Hait is Global Head of myeloma. We greatly appreciate the 2 3 2. Left to right: Paula and Warren will cure multiple myeloma. Research and Development at Janssen enthusiasm, support and generosity Berliner, Lori and Joe Dobrin Research Development, LLC. of all who participated.” 3. W. Dana LaForge and The event, Fairfield County, Kathleen McCabe Connecticut’s largest fundraiser, World-class entertainment was 4. Elizabeth and Traver Hutchins was attended by more than 1,100 provided by Wynton Marsalis, the 5.  Left to Right: Linda Miller, Karen people, including many celebrities internationally acclaimed musician, Siebert, Hoda Kotb, Karen Andrews, and the nation’s most prominent composer, bandleader, educator, and 1. Left to right: William N. Hait, M.D., Anna Povinelli, Julie Church business executives and high-impact Managing and Artistic Director of Ph.D., Brian Williams, Tom Brokaw, Kathy Giusti, Wynton Marsalis, Walter M. Capone philanthropists. Jazz at Lincoln Center. 2.  Skip Brevis Band Brian Williams, Anchor and Managing “Hosting this event is extremely 3. Wynton Marsalis Editor of NBC Nightly News, served as gratifying,” says Walter M. Capone, 4.  David Letterman Master of Ceremonies. Tom Brokaw, Chief Executive Officer and President 5. Brian Williams

EVENTS 19 4 5 Laugh for Life Raises $700,000

1 3

Chicago 2 Awards Dinner 1 2 3 Raises $800,000 4 5

6 4 5 6

April was an encouraging month for the faster and one day the MMRF will find a at CBS 2 Chicago and a multiple Fran Drescher was the honoree at common cause, developing a plan to MMRF. That is when more than 400 cure. I am honored to be recognized by myeloma patient, and Lester Knight, the 12th Annual Multiple Myeloma “No organization is doing achieve that cause, and staying with business, healthcare and community the MMRF, an innovative organization Founding Partner and Co-Chairman Research Foundation Laugh for Life: it until the goal is achieved,” said Joel leaders attended the 12th Annual that helps so many cancer patients.” of RoundTable Healthcare Partners. New York evening held in May. Susie more to shape the future Beetsch, Vice President of Global Patient Multiple Myeloma Research Foundation Essman, stand-up comedian, actress, of cancer research.” Advocacy at Celgene Corporation. Connie L. Lindsey, Executive Vice “We are truly grateful for the remark- Chicago Awards Dinner to honor writer, television producer, and voice “Celgene is proud to partner with the President and Global Head of able support shown tonight by our legendary NFL player, head coach and artist, served as headliner for the — Fr an Drescher MMRF on behalf of the many, many Corporate Social Responsibility speakers Bonnie Hunt, Mike Ditka and broadcaster Mike Ditka. The event comedy event. Michael Reinert, Partner patients and families it serves.” and Global Diversity & Inclusion at Connie Lindsey,” said Walter M. Capone, raised more than $800,000, which at Fox Rothschild LLP and a member Northern Trust, Chicago, served as MMRF Chief Executive Officer and courage of patients, their families and will help extend patients’ lives and of the MMRF Board of Directors, was the event’s Patient Family Speaker. President. “Together we are playing friends,” said Walter M. Capone, Chief accelerate new treatments leading the evening’s Master of Ceremonies. a vital role in the development of Executive Officer and President of the to a cure for multiple myeloma. “I am here this evening with a heart filled They were joined by more than 625 new and improved treatments for MMRF. “Thanks to those who inspire with gratitude and a sense of urgency,” tri-state area business, healthcare Mr. Ditka was presented with the cancer patients.” and support events like ‘Laugh,’ we said Ms. Lindsey. “I am grateful for and community leaders who raised MMRF Courage and Commitment are able to accelerate new and even the MMRF and to Kathy Giusti whose $700,000 to benefit the innovative Award by the 2012 MMRF Spirit of more effective therapies for patients indefatigable pursuit of excellence research conducted by the MMRF. Hope Award Honoree, Pat Williams, and advance cutting-edge research and collaborative scientific research 1. Elizabeth Hutchins Senior Vice President of the NBA’s 1. Pat Williams, Walter M. Capone, Connie Lindsey, “The MMRF Laugh for Life event through our partnerships with the best transformed the approach to treatment 2. Walter M. Capone, Fran Drescher, Michael Orlando Magic. Kathy Giusti, Bonnie Hunt, Mike Ditka provides us the opportunity to honor scientists, researchers and clinicians in Reinert, Aviva Drescher, Anne Quinn Young options for myeloma patients.” 2. Mike Ditka all who are united in our mission to institutions and companies worldwide.” 3. Susie Essman “By funding valuable cancer research 3. The Rosengarden Family with Mike Ditka The event was also attended by notable cure myeloma, but especially the 4. Fran Drescher, Sherri Lippman, Sue Korn, and breaking down barriers in cancer 4. Pat Williams “The MMRF is known for bringing great Cindi Stern Chicago guests including Derrick research,” Mr. Ditka said, “countless 5. Ryan Anthony researchers, scientists and the multiple 5. Skip Brevis Band Blakley, General Assignment Reporter patients will be able to get treatments 6. Connie Lindsey myeloma community together for a 6. Aviva Drescher, Michael Reinert

20 THEMMRF.ORG EVENTS 21 Chicago

Honorary Race Co-chairs: Dr. Andrej Jakubowiak Team for Cures 5K Walk/Run and Dr. Todd Zimmerman, Team for Cures 5K has raised more than $2 million with nearly 10,000 The University of Chicago Medicine participants so far in 2014! The series is held annually in seven cities and participation Attendees: ...... 1,791 Spirit of Hope Honoree: family donate to the MMRF rather Funds Raised: ...... $539,340 Eli Coustan offers camaraderie and knowledge sharing for patients, patient family members and friends, than give him presents for his seventh Top Team: 410 for Jill...... $78,225 Eli got involved with the MMRF so birthday in August. Whenever anyone members of the myeloma community, and others. Top Individual: that he could help raise awareness and asks why he is fundraising, he always Hal Anderson ...... $17,390 funds to cure multiple myeloma to save gives the same simple response, “I want to help save Uncle Brad.” Eli raised San Francisco Boston his uncle Brad. Eli also decided that he would prefer to have his friends and $14,363 for the MMRF. Spirit of Hope Honorees: Allan Osborne Twin Cities Tri-State (CT, NJ, NY)

When Allan and his wife Deb realized Honorary Race Co-chairs: Honorary Race Co-chairs: MMRF Courage and Commitment that the drugs responsible for Allan’s Dr. Shaji Kumar, Mayo Clinic Kathy Giusti Award Recipient: Mark Herzlich, remission were due to the work of and Walter M. Capone, MMRF New York Giants linebacker and Attendees: ...... 1,134 Honorary Race Co-chairs: the MMRF, they wanted to help the bone cancer survivor Funds Raised: ...... $170,336 Attendees: ...... 1,263 Dr. Paul Richardson, Dana-Farber research move forward. The Osbornes After his diagnosis Top Team: TEAM TIR(ED) ...... $20,793 Funds Raised: ...... $343,400 Cancer Institute and Dr. Michael and their friends have participated in in 2009, Herzlich Top Individual: Top Team: Vasconcelles, Millennium, Takeda every event since 2010. was told he would Ericka Johnson ...... $1,980 Team Better Days...... $108, 830 Oncology Company never play football Honorary Race Co-chairs: Top Individual: Gary Heinze ...$11,418 again, and that his Dr. Tom Martin and Dr. Jeffrey Wolf, Attendees: ...... 1,829 Spirit of Hope Honorees: survival odds were University of California San Francisco Funds Raised: ...... $360,576 Megan Parker 10 percent. Two Top Team: Attendees: ...... 750 Megan started fundraising for the years later, he was Team Multiple Miracles...... $22,075 Funds Raised: ...... $225,633 MMRF to support her mother and a member of the Top Individual: Paul Carter ....$18,560 Top Team: Team Susie...... $26,196 continues to fundraise after her death. Super Bowl XLVI Spirit of Giving Award: Top Individual: Jack Aiello .....$45,606 Spirit of Hope Honorees: On long runs, she would break down Championship Giants team. Herzlich Maureen Willard Team Jeffy C & TNT in tears thinking about her. “There is shared his inspirational story and signed Spirit of Hope Honorees: Hurley Nation...... $11,747 This courageous and growing team, nothing more motivating than stopping hundreds of copies of his new book, Susie Castillo-Robson which has become very active in the someone else from feeing that pain. We What it Takes: Fighting for My Life and and Robert Robson multiple myeloma community, works must find a cure.” My Love of the Game at the race. After Susie was diagnosed with multiple in support of all cancer patients, and myeloma, she said, “I wanted my years specifically in honor of Jeff Carlson and to matter. We decided the MMRF 5K Nate Tatarek. The MMRF 5K is a time for Walk/Run fit the bill for truly making an Jeff and Nate’s families to come together impact because the MMRF spearheads and remember Jeff who, sadly, passed such important and urgent work.” away in 2012 at the young age of 34, and honor Nate (coincidentally a friend and co-worker of Jeff’s) who continues to fight this disease daily.

22 THEMMRF.ORG EVENTS 23 Endurance events Independent events Amazing families put their passion to work and hosted more than 90 events that raised close to $1 million for the MMRF in 2014.

Crawfish for Cancer Second Annual #bradstrong

Eric Gelber (center) 200 Miles Towards a Cure Golfs Against Cancer 2,185.3 miles on to Benefit the MMRF

® 200 Miles Towards a Cure IRONMAN Lake Placid the Appalachian Trail Golf is a popular way to fundraise for the MMRF. In 2014, over 20 golf Super-supporter and ultra-runner 110 athletes raised $865,000 in Mark St. John took time between jobs tournaments were hosted across the Eric Gelber, who has raised more than the prestigious IRONMAN Lake to hike the entire Appalachian Trail, country, raising more than $400,000 $470,000 since 2008 via various ultra- Placid triathlon in July. The MMRF a five-month journey that resulted in for critical myeloma research. marathon events, raised the bar even is the exclusive charity partner of over $10,000 raised for the MMRF. higher this year by attempting to run IRONMAN Lake Placid, one of the Mark made his epic journey to honor his The tournament that had the biggest 200 miles, in New York City’s Central most popular IRONMAN races. friend Paula Guerin, who lost her battle growth this year was hosted by Brad Park, Friday, Sept. 19 to Sunday 21. With Triathletes completed the 2.4-mile with multiple myeloma in 2011. Coustan, who was diagnosed with the support of Celgene Corporation, swim, 112-mile bike ride and 26.2-mile Young philanthropists at a Crawfish for Cancer event multiple myeloma in 2012. who recruited 33 employees to serve as marathon to cross the finish line and Crawfish for Cancer (CFC Inc.) was “lap captains,” Eric ran for an amazing 56 hear those magic words, “You are an New in 2015: CFC has grown from one event held The #bradstrong Golfs Against Cancer hours, raising over $215,000. Hundreds founded by James Crowell, whose each May in New York City to six events Golf Outing to Benefit the MMRF is held IRONMAN.” And six MMRF athletes n Spartan Stadium obstacle races in Citi Field father, Lieutenant Colonel Lorenzo across the country in Atlanta, Boston, in Scotts Plains, New Jersey with over of runners joined him during the course earned a spot in the IRONMAN and Fenway Park. VIP experience for Mayo Crowell, USAF, Retired, passed Chicago, D.C., New York City and San 140 golfers and about 200 participants. of the two-plus days, including scores of World Championships in Kona, HI, the individuals and corporate teams. away as a result of multiple myeloma multiple myeloma patients who walked ultimate goal for triathletes. Visit our Francisco. Hundreds of pounds of The event doubled its revenue this year, n Ragnar Relays — 12-person, 200-mile or ran with him to show gratitude in March 2014. Louisiana crawfish are served along with raising over $51,000 for the MMRF. website to see how the IRONMAN running experiences are on the bucket and support. Eric’s effort was part of beer, wine and signature cocktails, with program is expanding in 2015. list for many runners. Fellow Williams College alumni and the MMRF Your Own Race program, live music throughout the day. n Kayak for a Cause — 100 kayakers will cofounders Peter Vecchio, Michael where athletes can take on an athletic cross Long Island Sound.. Graham and Scott Johnson helped The MMRF has received more than adventure or race of their choosing. Learn more and get involved: James launch CFC in 2008. Their idea $150,000 over the past five years and Challenging endurance themmrf.org/TeamForCures was to provide events that cater to $80,000 for CFC’s 2014 events. The young professionals and engage a 2015 Crawfish events promise to be events raised over new generation of philanthropists. even bigger with a season kick-off event The goal was to raise awareness and $3 million in 2014. Glenn Pagan, IRONMAN® World in Charleston, SC on April 11, 2015. Championships, Kona, HI. funds for multiple myeloma research. Brad Coustan and family.

24 THEMMRF.ORG EVENTS 25 MMRF in the news accelerator The Magazine of the Multiple Myeloma The MMRF has a compelling story to tell 2015 Calendar of Events Research Foundation | Fall/Winter 2014

And the world wants to hear it. MMRF Signature Events Multiple Myeloma Research Foundation Spring 2015 MMRF Chicago Awards Dinner Chicago, IL 383 Main Avenue, 5th Floor, Norwalk, CT 06851 Phone: 203-229-0464 Email: [email protected] May 5, 2015 MMRF Laugh for Life: New York New York, NY Fax 203-229-0572 Web: themmrf.org October 24, 2015 MMRF Annual Fall Gala Greenwich, CT Fortune Magazine The MMRF Online: The March issue of Fortune Magazine named Kathy Giusti number 19 of MMRF Endurance Events March 15, 2015 New York City Half Marathon Register Online “The World’s 50 Greatest Leaders,” putting her in the company of the Pope Board of Directors and the Dalai Llama. March 22, 2015 Quintiles Marathon and Half Marathon Register Online Kathy Giusti, Executive Chairman, Founder April 20, 2015 Boston Marathon Register Online Kenneth Anderson, M.D. Gerald McDougall Karen E. Andrews William S. McKiernan April 26, 2015 Virgin London Marathon Register Online William K. Bowes, Jr. Chris A. McWilton Walter M. Capone Mike Mortimer April 26, 2015 Big Sur International Marathon Register Online Harvard Business School Club of New York Stephen Grand Charles B. Ortner May 3, 2015 TD Five Boro Bike Tour Register Online Eugene P. Grisanti David R. Parkinson, M.D. In May, the largest alumni chapter of the Harvard Business School (HBS) awarded David L. Lucchino Marie Pinizzotto, M.D. May 9, 2015 Santa Barbara Wine Country Half Marathon Register Online the John C. Whitehead Social Enterprise Award to Kathy Giusti in recognition of W. Dana LaForge Michael Reinert May 9, 2015 Spartan Citi Field Sprint (Stadium) Coming Soon Joel S. Marcus Meryl Zausner her profound commitment to social enterprise. Lori Tauber Marcus June 7, 2015 Escape from Alcatraz Register Online Executive Committee June 27, 2015 Kayak for a Cause Coming Soon Walter M. Capone July 19, 2015 New York City Triathlon Register Online President and Chief Executive Officer Fiona An, M.D. More Magazine ® July 26, 2015 IRONMAN Lake Placid Register Online Senior Vice President of Clinical Research The July issue of More Magazine featured Kathy Giusti in an article entitled, “One August 16, 2015 IRONMAN® Mont Tremblant Register Online Daniel Auclair, Ph.D. Vice President of Translational Research of These Women Might Save Your Life.” The article cited Kathy for “speeding up the September 29, 2015 BMW Berlin Marathon Register Online Beverly Harrison pace of cancer research” and provided a crystal clear explanation of how the MMRF September 2015 Ragnar Relay D.C. Coming Soon Vice President of Clinical Operations September 2015 Fifth Avenue Mile Coming Soon Anne Quinn Young, M.P.H. has achieved so much in such a short time. Vice President, Development October 10, 2015 IRONMAN® World Championship Kona Register Online and Strategic Partnerships October 11, 2015 Bank of America Chicago Marathon Register Online Sharon Saias Senior Director, Marketing FasterCures’ Innovator Spotlight November 1, 2015 TCS New York City Marathon Coming Soon Laura Gilman Director, Corporate and Independent Events In July, FasterCures, a Center of the Milken Institute, interviewed Walter M. Capone November 2015 Spartan Fenway Park Sprint (Stadium) Coming Soon Honorary Board as one of the “people driving some of the most promising consortia in medical MMRF 5K Walks/Runs Dusty Baker Dan Jansen research.” Walter’s interview is part a series that comprises FasterCures’ March 2015 San Francisco San Francisco, CA Don Baylor Hoda Kotb James T. Brown Diana Krall Consortia-pedia project, which dissects the research-by-collaboration model April 2015 Boston Boston, MA Bob Costas Eric McCormack Katie Couric Deborah Norville May 2015 Atlanta Atlanta, GA and aims to establish a framework that can be applied broadly. Cindy Crawford Sharon Osbourne June 2015 Tri-State (CT, NJ, NY) New Canaan, CT Ann Curry Carl Quintanilla Clive J. Davis Al Roker September 2015 Chicago Chicago, IL Scott Hamilton Mel Stottlemyre September 2015 Twin Cities St. Paul, MN Mariska Hargitay Brian Williams Wired Magazine Lou Holtz Pat Williams The August issue of Wired Magazine carried an article written by Kathy Giusti titled October 2015 New Jersey/New York TBD Bonnie Hunt Bob Woodruff Senator Kay Bailey Lee Woodruff “Cancer Research: Not a One-Size-Fits-All Approach.” Kathy wrote about recent November 2015 Philadelphia Philadelphia, PA Hutchison November 2015 Washington, D.C. Fort Washington, MD advances in genome sequencing technologies and super computers making it possible to “ferret out the genetic mutations and other molecular abnormalities Clinical Insights in Multiple Myeloma that underlie certain cancers.” Kathy went on to explain that “this information is April 2015 Chairs: Drs. Paul Richardson & Kenneth Anderson Dana-Farber Cancer Institute Boston, MA one of the most important resources cancer patients can have because it can allow May 2015 Chair: Drs. Sagar Lonial & Jonathan Kaufman doctors to tailor treatments to the unique aspects of their cancer.” The information herein is not intended to replace the Winship Cancer Center Atlanta, GA services of trained health professionals (or to be a substitute for medical advice). You are advised to consult with your healthcare professional with regard to matters relating to your June 2015 Chair: Dr. Sundar Jagannath health and, in particular, regarding matters which may require Mt. Sinai Hospital New York, NY diagnosis or medical attention. To read more, visit themmrf.org/stories Copyright ©2014 Multiple Myeloma Research Foundation

26 MMRF IN THE NEWS THEMMRF.ORG 27 383 Main Avenue, 5th Floor, Norwalk, CT 06851

we are curing cancer

THIS CAMPAIGN WILL ENABLE US TO ACCOMPLISH AS MUCH IN THE NEXT THREE YEARS AS WE HAVE IN THE PAST DECADE.

We are fueling the development of treatments that have real promise for patients who don’t have time to waste. We have built a strong foundation and a proven network that is ready to leverage new science and technology to further accelerate success. This is a very special moment in time. The impact of each dollar will be exponentially magnified by our momentum. All of our needs are immediate and the return on the investment will be realized equally fast.

PLEASE SUPPORT THE MMRF NOW CAMPAIGN. DONATE AT THEMMRF.ORG

GUIDESTAR®